The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101.
 
Matthew H. G. Katz
No Relationships to Disclose
 
Qian Shi
No Relationships to Disclose
 
Syed A. Ahmad
No Relationships to Disclose
 
Joseph M. Herman
Employment - Merrimack
Stock and Other Ownership Interests - Merrimack
Honoraria - Celgene
Patents, Royalties, Other Intellectual Property - Elekta corporation
 
Robert de Wilton Marsh
No Relationships to Disclose
 
Eric Andrew Collisson
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - Castlight Health; Guardant Health; NantHealth
Research Funding - Daiichi Sankyo (Inst); Guardant Health (Inst)
Other Relationship - Roche/Genentech
 
Lawrence H. Schwartz
Honoraria - Merck KGaA; Pfizer
Patents, Royalties, Other Intellectual Property - Varian Medical Systems
Other Relationship - BioClinica; ICON Clinical Research
 
Robert C. G. Martin
No Relationships to Disclose
 
William Charles Conway
No Relationships to Disclose
 
Mark Truty
No Relationships to Disclose
 
Hedy Lee Kindler
No Relationships to Disclose
 
Andrew M. Lowy
Honoraria - Celgene; Pfizer
Consulting or Advisory Role - Halozyme; Merck Sharp & Dohme
Travel, Accommodations, Expenses - Celgene
 
Philip Agop Philip
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Novartis; Roche; Sanofi
Consulting or Advisory Role - Bayer; Celgene; epson; Lilly; novartis; Roche
Speakers' Bureau - Amgen; Bayer; Celgene; roche; sanofi
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Roche (Inst)
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly; NCCN; Pfizer; Regeneron; Sirtex Medical; Taiho Pharmaceutical
Research Funding - NCCN; NCI; Oncolytics
Other Relationship - Exelixis; Polaris
 
Dana Backlund Cardin
No Relationships to Disclose
 
Noelle K. LoConte
No Relationships to Disclose
 
Alan P. Venook
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Onyx (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech; Halozyme; Merck Serono; Roche